- Home
- PHUN vs TVRD Comparison
PHUN vs TVRD Comparison
Compare PHUN & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | TVRD |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 34.1M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHUN | TVRD |
|---|---|---|
| Price | $1.66 | $3.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.25 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 209.6K | 53.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,883,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $95.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $3.50 |
| 52 Week High | $3.88 | $43.65 |
Technical Indicators
Market Signals| Indicator | PHUN | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 42.49 |
| Support Level | $1.56 | N/A |
| Resistance Level | $2.04 | $4.52 |
| Average True Range (ATR) | 0.12 | 0.30 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 23.08 | 28.19 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.